Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study Academic Article uri icon

Overview

MeSH Major

  • Adrenergic beta-1 Receptor Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Atenolol
  • Cardiovascular Diseases
  • Losartan

abstract

  • We showed a greater beneficial effect of losartan versus atenolol-based antihypertensive treatment in the group of patients older than 67 years compared to the group of patients younger than 67 years. This difference was not explained by a more pronounced effect of losartan-based treatment on any of the cardiovascular risk factors demonstrated to have independent prognostic importance.

publication date

  • June 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/HJH.0b013e328352f7f6

PubMed ID

  • 22499288

Additional Document Info

start page

  • 1252

end page

  • 9

volume

  • 30

number

  • 6